|
Gene: NUCB2 |
Gene summary for NUCB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NUCB2 | Gene ID | 4925 |
Gene name | nucleobindin 2 | |
Gene Alias | HEL-S-109 | |
Cytomap | 11p15.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q2L696 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4925 | NUCB2 | EEC-subject2 | Human | Endometrium | EEC | 4.81e-15 | -4.47e-01 | -0.2607 |
4925 | NUCB2 | EEC-subject3 | Human | Endometrium | EEC | 1.78e-29 | -5.25e-01 | -0.2525 |
4925 | NUCB2 | EEC-subject5 | Human | Endometrium | EEC | 1.99e-02 | -1.27e-01 | -0.249 |
4925 | NUCB2 | GSM5276934 | Human | Endometrium | EEC | 4.75e-09 | -3.49e-01 | -0.0913 |
4925 | NUCB2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.49e-25 | -4.04e-01 | -0.1869 |
4925 | NUCB2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.65e-26 | -4.01e-01 | -0.1875 |
4925 | NUCB2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.75e-25 | -3.38e-01 | -0.1883 |
4925 | NUCB2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.72e-26 | -2.84e-01 | -0.1934 |
4925 | NUCB2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.58e-44 | -6.04e-01 | -0.1917 |
4925 | NUCB2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.51e-46 | -5.79e-01 | -0.1916 |
4925 | NUCB2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 9.57e-15 | -4.72e-01 | -0.1269 |
4925 | NUCB2 | LZE4T | Human | Esophagus | ESCC | 3.16e-11 | 5.70e-01 | 0.0811 |
4925 | NUCB2 | LZE7T | Human | Esophagus | ESCC | 2.75e-05 | 3.85e-01 | 0.0667 |
4925 | NUCB2 | LZE24T | Human | Esophagus | ESCC | 1.37e-09 | 6.54e-01 | 0.0596 |
4925 | NUCB2 | LZE21T | Human | Esophagus | ESCC | 2.09e-02 | 1.00e-01 | 0.0655 |
4925 | NUCB2 | P1T-E | Human | Esophagus | ESCC | 5.17e-04 | 4.62e-01 | 0.0875 |
4925 | NUCB2 | P2T-E | Human | Esophagus | ESCC | 2.57e-25 | 6.67e-01 | 0.1177 |
4925 | NUCB2 | P4T-E | Human | Esophagus | ESCC | 2.71e-43 | 1.25e+00 | 0.1323 |
4925 | NUCB2 | P8T-E | Human | Esophagus | ESCC | 4.81e-34 | 1.14e+00 | 0.0889 |
4925 | NUCB2 | P9T-E | Human | Esophagus | ESCC | 1.62e-20 | 7.74e-01 | 0.1131 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166714 | Breast | IDC | response to nutrient levels | 62/1434 | 474/18723 | 2.33e-05 | 5.57e-04 | 62 |
GO:003166723 | Breast | DCIS | response to nutrient levels | 58/1390 | 474/18723 | 1.16e-04 | 2.03e-03 | 58 |
GO:00321021 | Breast | DCIS | negative regulation of response to external stimulus | 46/1390 | 420/18723 | 5.19e-03 | 3.81e-02 | 46 |
GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
GO:00316671 | Colorectum | SER | response to nutrient levels | 106/2897 | 474/18723 | 3.94e-05 | 1.00e-03 | 106 |
GO:00316672 | Colorectum | MSS | response to nutrient levels | 125/3467 | 474/18723 | 1.24e-05 | 2.88e-04 | 125 |
GO:003166716 | Endometrium | AEH | response to nutrient levels | 78/2100 | 474/18723 | 3.26e-04 | 3.64e-03 | 78 |
GO:003166717 | Endometrium | EEC | response to nutrient levels | 82/2168 | 474/18723 | 1.23e-04 | 1.64e-03 | 82 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:003166712 | Liver | Cirrhotic | response to nutrient levels | 174/4634 | 474/18723 | 3.08e-09 | 1.27e-07 | 174 |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
GO:0031667110 | Oral cavity | LP | response to nutrient levels | 165/4623 | 474/18723 | 3.87e-07 | 1.12e-05 | 165 |
GO:00321023 | Oral cavity | EOLP | negative regulation of response to external stimulus | 75/2218 | 420/18723 | 1.74e-04 | 1.80e-03 | 75 |
GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
GO:003210212 | Oral cavity | NEOLP | negative regulation of response to external stimulus | 63/2005 | 420/18723 | 3.67e-03 | 2.14e-02 | 63 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NUCB2 | SNV | Missense_Mutation | novel | c.455C>G | p.Ser152Cys | p.S152C | protein_coding | deleterious(0.03) | possibly_damaging(0.8) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
NUCB2 | SNV | Missense_Mutation | novel | c.835N>A | p.Asp279Asn | p.D279N | protein_coding | tolerated(0.11) | benign(0.024) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD | |
NUCB2 | SNV | Missense_Mutation | novel | c.1000N>A | p.Glu334Lys | p.E334K | protein_coding | tolerated(0.15) | benign(0.177) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
NUCB2 | SNV | Missense_Mutation | c.1107N>T | p.Gln369His | p.Q369H | protein_coding | tolerated(0.23) | possibly_damaging(0.51) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
NUCB2 | SNV | Missense_Mutation | c.508N>T | p.Asp170Tyr | p.D170Y | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
NUCB2 | SNV | Missense_Mutation | c.948N>T | p.Glu316Asp | p.E316D | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
NUCB2 | deletion | Frame_Shift_Del | c.1193delN | p.Lys400AsnfsTer15 | p.K400Nfs*15 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||||
NUCB2 | insertion | Frame_Shift_Ins | novel | c.749dupT | p.Lys251GlnfsTer4 | p.K251Qfs*4 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
NUCB2 | deletion | Frame_Shift_Del | c.1193delN | p.Lys400AsnfsTer15 | p.K400Nfs*15 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||||
NUCB2 | SNV | Missense_Mutation | c.679N>T | p.Asp227Tyr | p.D227Y | protein_coding | deleterious(0.02) | probably_damaging(0.982) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4925 | NUCB2 | DRUGGABLE GENOME | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 31327267 |
Page: 1 |